Bazedoxifene: A guide to its use in postmenopausal osteoporosis

Drugs and Aging

Volumn 29, Issue 4, 2012, Pages 329-334

  Keating, Gillian M ^a   Lyseng Williamson, Katherine A ^a   Duggan, Sean T ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Bazedoxifene; Fracture; Postmenopausal osteoporosis.

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CALCIUM; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BREAST CARCINOMA; BREAST CYST; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FRAGILITY FRACTURE; HEART INFARCTION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LEG CRAMP; LUNG EMBOLISM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

FEMALE; FRACTURES, BONE; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84859456411     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11207810-000000000-00000     Document Type: Review

References (22)

1. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010; 17 (1): 25-54
2. Prevention and management of osteoporosis: report of a WHO scientific group (WHO technical report series 921). Geneva: World Health Organisation, 2003
3. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005; 27 (1): 1-11 (Pubitemid 40342573)
4. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2010; 70 (18): 65-78
5. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis inpostmenopausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428
6. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148 (3): 197-213 (Pubitemid 351665507)
7. Clinicians guide to the prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010
8. Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007; 24 (5): 361-79 (Pubitemid 46790261)
9. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005 Sep; 146 (9): 3999-4008 (Pubitemid 41175771)
10. Duggan ST, McKeage K. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 2011; 71 (16): 2193-212
11. Conbriza 20mg film-coated tablets: EU summary of product characteristics. London: European Medicines Agency, 2011 Jun 27
12. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23 (12): 1923-34
13. Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009 Jun; 44 (6): 1049-54
14. World Health Organisation Collaborating Centre for Metabolic Bone Diseases. FRAX WHO fracture risk assessment tool [online]. Available from URL: http:/www. sheffield.ac.uk/FRAX/ [Accessed 2012 Jan 18]
15. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012 Jan; 23 (1): 351-63
16. Palacios S, Silverman S, Levine AB, et al. Longterm efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebocontrolled study [oral presentation]. 13th International Menopause Society World Congress on Menopause; 2011 Jun 8-11; Rome
17. Christiansen C, Chesnut CH, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskel Dis 2010 Jun 22; 11: 130
18. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16 (6): 1109-15
19. De Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebocontrolled phase 3 trial. Osteoporos Int 2011; 22: 567-76
20. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010 Oct; 21 (10): 1657-80
21. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010 Jan-Feb; 17 (1): 25-54
22. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428